Novartis’ GIST Drug, Glivec, Receives European Commission Approval

Novartis announced earlier today that the European Commission has approved an update to their Glivec (imatinib) label to include 36 months of treatment after surgery, for adults with KIT (CD117)-positive gastrointestinal stromal tumours (GIST) who met the inclusion conditions of the pivotal study. The prolonged treatment has been demonstrated to increase recurrence-free survival and the

Continue Reading

Europe Approves AstraZeneca’s Caprelsa for Medullary Thyroid Cancer

AstraZeneca announced earlier today that the European Commission has granted marketing authorisation for their thyroid cancer pill, Caprelsa (vandetanib). The approval was given for the treatment of aggressive and symptomatic medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease.  The announcement comes three months after the European Medicines Agency’s Committee for

Continue Reading

Bayer To Submit Regorafenib After Positive Survival Statistics

Bayer has provided more information about their recently-halted late-stage trial of their colorectal cancer drug, regorafenib, which shows that the drug improved overall survival by 29%, meeting its primary endpoint. In October, the Phase III CORRECT (Colorectal cancer treated with regorafenib or placebo after failure of standard therapy) trial, which contained 760 patients with metastatic

Continue Reading

GSK’s Tykerb Fails to Meet Trial Targets

GlaxoSmithKline has suffered a setback from the news that Tykerb has failed a late-stage trial investigating whether adjuvant treatment with the drug improves disease-free survival in women with early-stage HER2 positive breast cancer. Results have been presented at the San Antonio Breast Cancer Symposium from TEACH (Tykerb Evaluation After Chemotherapy), a Phase III randomised, double-blind,

Continue Reading

ASCO Report Argues Clinical Research Needs to Keep Up with Cancer Science

A new approach to therapy development, ‘smarter’, faster clinical trials and optimisation of health information technology are needed to deliver fully on the innovative advances in cancer seen in recent years, a new report claims. The report from the American Society of Clinical Oncology (ASCO), the world’s leading professional organization representing physicians who care for

Continue Reading